Biocon founder Kiran Mazumdar Shaw welcomes expert panel’s nod to Sputnik V.
On Monday, Kiran Mazumdar Shaw, the founder of Biocon, hailed the Subject Expert Committee (SEC) clearing Russia’s Sputnik V vaccine for emergency use in India as yet another step forward in India’s fight against Covid-19.
On hearing the news about a third vaccine making its way into India, Shaw said, “It adds to our armory. I hope it is one more step towards vaccinating the general population,” It is notable that currently, the health authorities in India are using Bharat Biotech’s Covaxin and Oxford’s Covishield to vaccinate eligible people.
Sputnik V is now waiting for the review by the Drugs Controller General of India (DCGI) and the Biocon founder hoped that it will be cleared by the regulator at the earliest.
She said, “I think there are many contracts manufactures Sputnik has identified. Initially India might import before going for indigenous manufacturing”. She further added that it was important for all of us to roll out as soon as possible. In a separate tweet, she also mentioned about completion of bridging trials by Sputnik V.
PC Mohan, Member of Parliament, Bangalore, also shared the news in a tweet and said that the Russian vaccine has shown an efficacy rate of 91.6%. He said, “Dr. Reddy's has partnered with the Russia Direct Investment Fund to bring the vaccine to India”.